Search tips
Search criteria 


Logo of jexpmedHomeThe Rockefeller University PressEditorsContactInstructions for AuthorsThis issue
J Exp Med. 1996 February 1; 183(2): 339–348.
PMCID: PMC2192466

HLA-derived peptides which inhibit T cell function bind to members of the heat-shock protein 70 family


Synthetic peptides corresponding to sequences of HLA class I molecules have inhibitory effects on T cell function. The peptides investigated in this study have sequences corresponding to the relatively conserved region of the alpha 1 helix of HLA class I molecules that overlaps the "public epitope" Bw4/Bw6. These HLA-derived peptides exhibit inhibitory effects on T lymphocytes and have beneficial effects on the survival of allogenic organ transplants in mice and rats. Peptides corresponding to the Bw4a epitope appear most potent as they inhibit the differentiation of T cell precursors into mature cytotoxic T lymphocytes (CTL) and target cell lysis by established CTL lines and clones. To elucidate the mechanism through which these peptides mediate their inhibitory effect on T lymphocytes, peptide binding proteins were isolated from T cell lysates. We show that the inhibitory Bw4a peptide binds two members of the heat-shock protein (HSP) 70 family, constitutively expressed HSC70 and heat-inducible HSP70. Peptide binding to HSC/HSP70 is sequence specific and follows the rules defined by the HSC70 binding motif. Most intriguing, however, is the strict correlation of peptide binding to HSC/HSP70 and the functional effects such that only inhibitory peptides bind to HSC70 and HSP70 whereas noninhibitory peptides do not bind. This correlation suggests that small molecular weight HLA-derived peptides may modulate T cell responses by directly interacting with HSPs. In contrast to numerous reports of HSP70 expression at the surface of antigen-presenting cells and some tumor cells, we find no evidence that HSC/HSP70 are expressed at the surface of the affected T cells. Therefore, we believe that the peptides' immunodulatory effects are not mediated through a signaling event initiated by interaction of peptide with surface HSP, but favor a model similar to the action of other immunomodulatory compounds, FK506 and cyclosporin A, with a role for HSC/HSP70 similar to that for immunophilins, FKBPs and CyP40.

Full Text

The Full Text of this article is available as a PDF (1.3M).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Opelz G, Terasaki PI. Improvement of kidney-graft survival with increased numbers of blood transfusions. N Engl J Med. 1978 Oct 12;299(15):799–803. [PubMed]
  • Blumberg N, Triulzi DJ, Heal JM. Transfusion-induced immunomodulation and its clinical consequences. Transfus Med Rev. 1990 Oct;4(4 Suppl 1):24–35. [PubMed]
  • van Twuyver E, Mooijaart RJ, ten Berge IJ, van der Horst AR, Wilmink JM, Kast WM, Melief CJ, de Waal LP. Pretransplantation blood transfusion revisited. N Engl J Med. 1991 Oct 24;325(17):1210–1213. [PubMed]
  • Davies HS, Pollard SG, Calne RY. Soluble HLA antigens in the circulation of liver graft recipients. Transplantation. 1989 Mar;47(3):524–527. [PubMed]
  • Sumimoto R, Kamada N. Evidence that soluble class I antigen in donor serum induces the suppression of heart allograft rejection in rats. Immunol Lett. 1990 Oct;26(1):81–84. [PubMed]
  • Clayberger C, Parham P, Rothbard J, Ludwig DS, Schoolnik GK, Krensky AM. HLA-A2 peptides can regulate cytolysis by human allogeneic T lymphocytes. Nature. 1987 Dec 24;330(6150):763–765. [PubMed]
  • Parham P, Clayberger C, Zorn SL, Ludwig DS, Schoolnik GK, Krensky AM. Inhibition of alloreactive cytotoxic T lymphocytes by peptides from the alpha 2 domain of HLA-A2. Nature. 1987 Feb 12;325(6105):625–628. [PubMed]
  • Krensky AM, Lyu SC, Pouletty P, Benjamin R, Parham P, Clayberger C. Peptides corresponding to the CD8 binding region of HLA class I block the differentiation of cytotoxic T lymphocyte precursors. Transplant Proc. 1993 Feb;25(1 Pt 1):483–484. [PubMed]
  • Clayberger C, Lyu SC, DeKruyff R, Parham P, Krensky AM. Peptides corresponding to the CD8 and CD4 binding domains of HLA molecules block T lymphocyte immune responses in vitro. J Immunol. 1994 Aug 1;153(3):946–951. [PubMed]
  • Clayberger C, Rosen M, Parham P, Krensky AM. Recognition of an HLA public determinant (Bw4) by human allogeneic cytotoxic T lymphocytes. J Immunol. 1990 Jun 1;144(11):4172–4176. [PubMed]
  • VAN ROOD JJ, VAN LEEUWEN A. LEUKOCYTE GROUPING. A METHOD AND ITS APPLICATION. J Clin Invest. 1963 Sep;42:1382–1390. [PMC free article] [PubMed]
  • D'Amaro J. W4(4a) and W6(4b) in diverse human populations. Demonstration of their genetic identity in population and segregation studies. Tissue Antigens. 1975 Jun;5(5):386–384. [PubMed]
  • Lawlor DA, Warren E, Taylor P, Parham P. Gorilla class I major histocompatibility complex alleles: comparison to human and chimpanzee class I. J Exp Med. 1991 Dec 1;174(6):1491–1509. [PMC free article] [PubMed]
  • Christiansen FT, Witt CS, Ciccone E, Townend D, Pende D, Viale D, Abraham LJ, Dawkins RL, Moretta L. Human natural killer (NK) alloreactivity and its association with the major histocompatibility complex: ancestral haplotypes encode particular NK-defined haplotypes. J Exp Med. 1993 Sep 1;178(3):1033–1039. [PMC free article] [PubMed]
  • Cella M, Longo A, Ferrara GB, Strominger JL, Colonna M. NK3-specific natural killer cells are selectively inhibited by Bw4-positive HLA alleles with isoleucine 80. J Exp Med. 1994 Oct 1;180(4):1235–1242. [PMC free article] [PubMed]
  • Gumperz JE, Litwin V, Phillips JH, Lanier LL, Parham P. The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J Exp Med. 1995 Mar 1;181(3):1133–1144. [PMC free article] [PubMed]
  • Clayberger C, Lyu SC, Pouletty P, Krensky AM. Peptides corresponding to T-cell receptor-HLA contact regions inhibit class I-restricted immune responses. Transplant Proc. 1993 Feb;25(1 Pt 1):477–478. [PubMed]
  • Krensky AM, Clayberger C. The induction of tolerance to alloantigens using HLA-based synthetic peptides. Curr Opin Immunol. 1994 Oct;6(5):791–796. [PubMed]
  • Nisco S, Vriens P, Hoyt G, Lyu SC, Farfan F, Pouletty P, Krensky AM, Clayberger C. Induction of allograft tolerance in rats by an HLA class-I-derived peptide and cyclosporine A. J Immunol. 1994 Apr 15;152(8):3786–3792. [PubMed]
  • Buelow R, Veyron P, Clayberger C, Pouletty P, Touraine JL. Prolongation of skin allograft survival in mice following administration of ALLOTRAP. Transplantation. 1995 Feb 27;59(4):455–460. [PubMed]
  • Cuturi MC, Josien R, Douillard P, Pannetier C, Cantarovich D, Smit H, Ménoret S, Pouletty P, Clayberger C, Soulillou JP. Prolongation of allogeneic heart graft survival in rats by administration of a peptide (a.a. 75-84) from the alpha 1 helix of the first domain of HLA-B7 01. Transplantation. 1995 Mar 15;59(5):661–669. [PubMed]
  • Zemmour J, Parham P. HLA class I nucleotide sequences, 1992. Immunogenetics. 1993;37(4):239–250. [PubMed]
  • Buxton SE, Benjamin RJ, Clayberger C, Parham P, Krensky AM. Anchoring pockets in human histocompatibility complex leukocyte antigen (HLA) class I molecules: analysis of the conserved B ("45") pocket of HLA-B27. J Exp Med. 1992 Mar 1;175(3):809–820. [PMC free article] [PubMed]
  • Krensky AM, Reiss CS, Mier JW, Strominger JL, Burakoff SJ. Long-term human cytolytic T-cell lines allospecific for HLA-DR6 antigen are OKT4+. Proc Natl Acad Sci U S A. 1982 Apr;79(7):2365–2369. [PubMed]
  • Cleveland DW, Fischer SG, Kirschner MW, Laemmli UK. Peptide mapping by limited proteolysis in sodium dodecyl sulfate and analysis by gel electrophoresis. J Biol Chem. 1977 Feb 10;252(3):1102–1106. [PubMed]
  • Fischer SG. Peptide mapping in gels. Methods Enzymol. 1983;100:424–430. [PubMed]
  • Fourie AM, Sambrook JF, Gething MJ. Common and divergent peptide binding specificities of hsp70 molecular chaperones. J Biol Chem. 1994 Dec 2;269(48):30470–30478. [PubMed]
  • Ullrich SJ, Robinson EA, Law LW, Willingham M, Appella E. A mouse tumor-specific transplantation antigen is a heat shock-related protein. Proc Natl Acad Sci U S A. 1986 May;83(10):3121–3125. [PubMed]
  • VanBuskirk AM, DeNagel DC, Guagliardi LE, Brodsky FM, Pierce SK. Cellular and subcellular distribution of PBP72/74, a peptide-binding protein that plays a role in antigen processing. J Immunol. 1991 Jan 15;146(2):500–506. [PubMed]
  • Ferrarini M, Heltai S, Zocchi MR, Rugarli C. Unusual expression and localization of heat-shock proteins in human tumor cells. Int J Cancer. 1992 Jun 19;51(4):613–619. [PubMed]
  • Manara GC, Sansoni P, Badiali-De Giorgi L, Gallinella G, Ferrari C, Brianti V, Fagnoni FF, Ruegg CL, De Panfilis G, Pasquinelli G. New insights suggesting a possible role of a heat shock protein 70-kD family-related protein in antigen processing/presentation phenomenon in humans. Blood. 1993 Nov 1;82(9):2865–2871. [PubMed]
  • Multhoff G, Botzler C, Wiesnet M, Müller E, Meier T, Wilmanns W, Issels RD. A stress-inducible 72-kDa heat-shock protein (HSP72) is expressed on the surface of human tumor cells, but not on normal cells. Int J Cancer. 1995 Apr 10;61(2):272–279. [PubMed]
  • Vanbuskirk A, Crump BL, Margoliash E, Pierce SK. A peptide binding protein having a role in antigen presentation is a member of the HSP70 heat shock family. J Exp Med. 1989 Dec 1;170(6):1799–1809. [PMC free article] [PubMed]
  • Udono H, Srivastava PK. Heat shock protein 70-associated peptides elicit specific cancer immunity. J Exp Med. 1993 Oct 1;178(4):1391–1396. [PMC free article] [PubMed]
  • Srivastava PK, Udono H, Blachere NE, Li Z. Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics. 1994;39(2):93–98. [PubMed]
  • Nadler SG, Tepper MA, Schacter B, Mazzucco CE. Interaction of the immunosuppressant deoxyspergualin with a member of the Hsp70 family of heat shock proteins. Science. 1992 Oct 16;258(5081):484–486. [PubMed]
  • Hoeger PH, Tepper MA, Faith A, Higgins JA, Lamb JR, Geha RS. Immunosuppressant deoxyspergualin inhibits antigen processing in monocytes. J Immunol. 1994 Nov 1;153(9):3908–3916. [PubMed]
  • Sigal NH, Dumont FJ. Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Annu Rev Immunol. 1992;10:519–560. [PubMed]
  • Friedman J, Weissman I. Two cytoplasmic candidates for immunophilin action are revealed by affinity for a new cyclophilin: one in the presence and one in the absence of CsA. Cell. 1991 Aug 23;66(4):799–806. [PubMed]
  • Liu J, Farmer JD, Jr, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 1991 Aug 23;66(4):807–815. [PubMed]
  • Fruman DA, Klee CB, Bierer BE, Burakoff SJ. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci U S A. 1992 May 1;89(9):3686–3690. [PubMed]
  • Fruman DA, Burakoff SJ, Bierer BE. Immunophilins in protein folding and immunosuppression. FASEB J. 1994 Apr 1;8(6):391–400. [PubMed]
  • Gething MJ, Sambrook J. Protein folding in the cell. Nature. 1992 Jan 2;355(6355):33–45. [PubMed]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press